Latest News

Yesterday
ASH23: CAR-T for autoimmune disease, real-world questions and sickle cell’s social media… BioPharma Dive20:33 9-Dec-23
STAT Plus: CAR-T, recently used in a lupus patient, helps other autoimmune patients, too, in… STAT15:32 9-Dec-23
STAT Plus: Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first… STAT12:36 9-Dec-23
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG5101 GlobeNewswire (Press Release)12:04 9-Dec-23
In the last 7 days
Vittoria’s CAR-T therapy secures clinical approval amid FDA scrutiny on sector Pharmaceutical Technology12:37 8-Dec-23
AbelZeta and AstraZeneca enter CAR-T cell therapy development deal Pharmaceutical Technology03:27 8-Dec-23
Galapagos to Host KOL Event on December 10, 2023, at 11:00 AM PST to discuss new data presented at ASH 2023 GlobeNewswire (Press Release)16:02 7-Dec-23
Cellectis shifts CAR-T manufacturing in-house, boosts efficacy compared to third-party CDMOs: #ASH23 ENDPOINTS12:30 7-Dec-23
LianBio rejects Concentra bid; Treadwell cuts workers; AstraZeneca inks CAR-T deal ENDPOINTS10:08 7-Dec-23
Life-saving cancer gene therapy under investigation after being linked to rare secondary cancers Chemistry World Magazine09:42 7-Dec-23
AbelZeta Pharma Announces Agreement with AstraZeneca to Co-Develop a novel Glypican 3 (GPC3)… PR Newswire (Press Release)08:04 7-Dec-23
Myasthenia Gravis Trial Set for CAR T CABA-201 American Journal of Managed Care09:15 6-Dec-23
CRISPR Overhauls CAR-T Pipeline With Next-Gen Candidates, Autoimmune Expansion Scrip Pharma Intelligence16:44 5-Dec-23
CAR-T safety risk a sign of maturing market, says ISCT head BioProcess Insider10:53 5-Dec-23
Carmot’s chance of beating the odds in the biotech market just ended STAT09:58 5-Dec-23
CRISPR Reorganizes CAR-T Pipeline Ahead of FDA’s Landmark Decision BioSpace09:49 5-Dec-23
CRISPR eyes autoimmune disease in revamp of cell therapy plans BioPharma Dive09:19 5-Dec-23
CAR-T therapies not cost-effective for diffuse large B-cell lymphoma Medical Xpress09:00 5-Dec-23
Top 5 Global Cell and Gene Therapy Manufacturer Selects ValGenesis for Digital Validation PR Newswire (Press Release)08:36 5-Dec-23
STAT Plus: New CAR-T company, Brainchild Bio, will focus first on brain tumors in children STAT07:06 5-Dec-23
CRISPR reprioritizes CAR-T pipeline with cuts, expands into autoimmune disease as US decision for exa-cel looms ENDPOINTS06:57 5-Dec-23
Following the US, Korean regulator obligates monitoring of CAR-T cell therapies Korea Biomedical Review00:53 4-Dec-23
In the last month
FDA’s CAR-T safety probe; AbbVie’s $10B ADC wager; Pfizer’s GLP-1 setback; Acelyrin’s CRO drama; and more ENDPOINTS06:03 2-Dec-23
Entendendo a terapia celular CAR-T e seus possíveis efeitos colaterais Newswise (Press Release)15:17 1-Dec-23
FDA opens investigation into potential cancer risks of Penn-pioneered CAR-T therapy The Daily Pennsylvanian22:17 30-Nov-23
FDA warns certain therapy to treat cancer may cause secondary cancer Scripps News14:42 30-Nov-23
Some car-T may very rarely cause new cancers The Niche (Weblog)09:47 30-Nov-23
Risk/Benefit Of CAR-T For Autoimmune Diseases May Shift With FDA Investigation Scrip Pharma Intelligence19:05 29-Nov-23
Clinicians say benefits of CAR-T continue to outweigh risk of T-cell malignancies ENDPOINTS15:59 29-Nov-23
FDA investigating risk of secondary cancers after CAR-T therapy to treat cancer CNN14:32 29-Nov-23
As FDA probes CAR-T safety, expert meeting for Bristol's Abecma could serve as key guidepost FiercePharma14:08 29-Nov-23
CAR-T Safety Probe Causes Alarm, But Is Unlikely To Upend Therapies Scrip Pharma Intelligence12:48 29-Nov-23
FDA opens investigation into secondary cancer risk with CAR-T therapies Pharmaceutical Technology12:36 29-Nov-23
A Cutting-Edge Cancer Treatment May Cause Cancer. The FDA Is Investigating WIRED12:23 29-Nov-23
Lifesaving cancer therapy may itself cause cancer, FDA warns Mail Online11:58 29-Nov-23
STAT Plus: Pharmalittle: FDA probes CAR-T therapy for links to lymphoma; White House official… STAT09:11 29-Nov-23
FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies PMLiVE07:46 29-Nov-23
FDA is investigating whether CAR-T, a cancer therapy pioneered at Penn, can cause lymphoma Medical Xpress06:59 29-Nov-23
STAT Plus: Blood cancers may arise from CAR-T cells, but experts think only in very rare cases STAT04:37 29-Nov-23
FDA Investigating 'Serious Risk' of Malignancy After CAR-T Therapy Medpage Today01:25 29-Nov-23
Innovative cancer treatment may sometimes cause cancer, FDA says The Seattle Times21:53 28-Nov-23
CAR-T, Lifesaving Cancer Treatment, May Sometimes Cause Cancer, FDA Says The New York Times20:45 28-Nov-23
FDA Launches Probe of Malignancies Linked to CAR-T Therapies BioSpace18:26 28-Nov-23
Volatile day for CAR-T biotechs after FDA announces cancer safety review FierceBiotech16:41 28-Nov-23
FDA investigating cancer risk linked to CAR-T cell therapy BioPharma Dive16:36 28-Nov-23
Cabaletta Bio’s and Gracell’s stock falls sharply as FDA investigates risks of CAR-T therapy MarketWatch16:00 28-Nov-23
FDA opens review of CAR-T safety after identifying 19 cases of post-treatment blood cancer ENDPOINTS14:54 28-Nov-23
US FDA investigating safety risk of CAR-T cancer therapies Reuters13:53 28-Nov-23
STAT Plus: FDA investigating whether CAR-T, a treatment for cancer, can also cause lymphoma STAT13:52 28-Nov-23
FDA launches wide probe into CAR-T therapy safety pharmaphorum13:48 28-Nov-23
FDA investigates 'serious risk' of secondary cancer following CAR-T treatment FiercePharma13:33 28-Nov-23
Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for … BioSpace09:03 27-Nov-23
Immix (IMMX) CAR-T Therapy IND Cleared by FDA, Stock Down Zacks10:32 22-Nov-23
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for… BioSpace09:38 22-Nov-23
Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for… GlobeNewswire (Press Release)09:28 22-Nov-23
Global CD19 Antibody Market and Clinical Pipeline Outlook 2023-2028: A $10 Billion+ Market by… Business Wire (Press Release)07:57 22-Nov-23
Novartis Looks To Lead CAR-T Expansion Into Autoimmune Disease Scrip Pharma Intelligence11:48 21-Nov-23
Nexcella Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing BioSpace11:35 21-Nov-23
Legend looks to Belgium plant opening as CAR-T expansions loom BioProcess Insider10:55 21-Nov-23
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201, Enabling U.S. Patient Dosing GlobeNewswire (Press Release)09:55 21-Nov-23
FDA delays assessment of BMS and 2seventy’s CAR-T therapy Pharmaceutical Technology08:33 21-Nov-23
Iaso Bio Set Up Car-T Treatment Centre In China To Serve Mm Patients Bernama01:49 21-Nov-23
Earnings call: Legend Biotech Reports Q3 Results, Announces Novartis Licensing Agreement Investing.com20:35 20-Nov-23
IASO Bio Establishes International CAR-T Diagnostic and Treatment Center in China to Serve MM… Business Wire (Press Release)20:31 20-Nov-23
CAR-T cell therapies infused into brain shrink tumors in two glioblastoma studies ENDPOINTS11:29 20-Nov-23
Bristol Myers and 2seventy bio say FDA delayed CAR-T therapy decision ENDPOINTS11:17 20-Nov-23
Week In Review: Legend Partners DLL3 CAR-T Candidate With Novartis In $1.2 Billion Deal Seeking Alpha02:11 19-Nov-23
CAR-T by Anixa Biosciences for Fallopian Tube Cancer: Likelihood of Approval Pharmaceutical Technology22:15 17-Nov-23
Call for national strategy to develop new cancer treatment Irish Examiner21:08 17-Nov-23
Global CD19 Antibody Market and Clinical Pipeline Outlook and Competitive Landscape: Insight on … PR Newswire (Press Release)14:02 17-Nov-23
Insurance Companies Flout State Laws Made to Safeguard Cancer Treatment Access Truthout10:58 17-Nov-23
Danaher/Abcam deal set to close next month; Cereno's loan; March Biosciences to advance its CAR-T into PhII ENDPOINTS10:53 17-Nov-23
Fierce Pharma Asia—Novartis, Legend's CAR-T deal; Astellas' busy week; Ajinomoto's $620M… FiercePharma08:05 17-Nov-23
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19… Nature.com05:21 16-Nov-23
Jiahui Health develops international CAR-T treatment platform in China PR Newswire (Press Release)22:13 15-Nov-23
Gilead’s Kite, Arcellx Expand BCMA CAR-T Partnership Into Lymphomas Scrip Pharma Intelligence17:38 15-Nov-23
Novartis and Legend Biotech Sign Exclusive License Agreement for CAR-T Therapies PharmTech.com14:03 15-Nov-23
Arcellx: A Strong Contender In The CAR-T Multiple Myeloma Market Seeking Alpha13:48 15-Nov-23
2seventy suffers sales slump on high production charges for BMS-partnered CAR-T med Abecma FiercePharma11:20 15-Nov-23
Legend and Novartis sign $100m CAR-T license agreement BioProcess Insider09:19 15-Nov-23
Novartis gains global rights to Legend’s CAR-T cell therapies in deal worth over $1bn PMLiVE07:28 15-Nov-23
Hemogenyx Pharmaceuticals PLC Announces Lentivirus Re-manufacturing Completed BioSpace02:40 15-Nov-23
Legend Biotech strikes deal with Novartis to advance small-cell lung cancer Biopharma Reporter07:17 14-Nov-23
Novartis signs agreement for Legend Biotech’s CAR-T therapies Pharmaceutical Technology06:00 14-Nov-23
Exploring CAR-T Therapy: A New Era in Cancer Treatment GlobeNewswire (Press Release)04:54 14-Nov-23
Novartis Enters into Deal with Legend Biotech for $100 Million Upfront BioSpace17:23 13-Nov-23
Novartis Teams Up With Legend, Moving CAR-T Into Solid Tumors Scrip Pharma Intelligence17:07 13-Nov-23
Legend and Novartis sign $100M deal for next CAR-T bets ENDPOINTS10:55 13-Nov-23
Novartis pays Legend $100M upfront to give solid tumor CAR-T the T-Charge treatment FierceBiotech10:45 13-Nov-23
Legend Biotech Announces Exclusive, Global License Agreement for Certain CAR-T Therapies… Business Wire (Press Release)08:33 13-Nov-23
Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update GlobeNewswire (Press Release)07:32 13-Nov-23
Vitamin D for Neuropathy; Good & Bad News for CAR-T; New Labeling for Surgical Mesh Medpage Today01:08 11-Nov-23
Lyell Immunopharma: Potential Solid Tumor Targeting With CAR-T And TIL Seeking Alpha14:25 10-Nov-23
Juventas Cell Therapy Announces the Approval of Its First Cell Therapy Product - Inaticabtagene Autoleucel by China NMPA AsiaOne12:12 10-Nov-23
Bristol Myers Squibb’s CAR-T Breyanzi wins FDA priority review Pharmaceutical Technology09:35 10-Nov-23
CAR-T biotech Cargo Therapeutics prices $281M IPO BioPharma Dive08:15 10-Nov-23
GenScript ProBio Signs Viral Vector Manufacturing MOU With Curocell for Next-Generation CAR-T… Business Wire (Press Release)00:01 10-Nov-23
CAR-T cell therapy biotech CARGO Therapeutics prices $281M IPO ENDPOINTS20:15 9-Nov-23
Implications of High Tumor Burden on Chimeric Antigen Receptor T-Cell Immunotherapy Journal of American Medical Associations11:51 9-Nov-23

      
            
      
    view more headlines
   
      
      
      
9 Dec 20:33
   

About our CAR-T news

Latest news on CAR-T (Chimeric Antigen Receptor T-cell) therapy, a type of cancer treatment that involves modifying patients' T-cells to recognize and attack cancer cells. In this therapy, T-cells are collected from the patient, engineered in a lab to express a specific receptor that binds to a protein on cancer cells, and then infused back into the patient to fight the cancer. CAR-T therapies have shown promise in treating certain types of blood cancers, like lymphoma and leukemia.

CAR-T

Latest News

About our CAR-T news

Cancer Top Stories

Health Top Stories

Lifestyle Top Stories